Can artificial parthenogenesis sidestep ethical pitfalls in human therapeutic cloning? An historical perspective

The aim of regenerative medicine is to reconstruct tissue that has been lost or pathologically altered. Therapeutic cloning seems to offer a method of achieving this aim; however, the ethical debate surrounding human therapeutic cloning is highly controversial. Artificial parthenogenesis—obtaining e...

Full description

Saved in:  
Bibliographic Details
Main Author: Fangerau, H. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2005
In: Journal of medical ethics
Year: 2005, Volume: 31, Issue: 12, Pages: 733-735
Online Access: Volltext (JSTOR)
Volltext (kostenfrei)
Volltext (kostenfrei)
Description
Summary:The aim of regenerative medicine is to reconstruct tissue that has been lost or pathologically altered. Therapeutic cloning seems to offer a method of achieving this aim; however, the ethical debate surrounding human therapeutic cloning is highly controversial. Artificial parthenogenesis—obtaining embryos from unfertilised eggs—seems to offer a way to sidestep these ethical pitfalls. Jacques Loeb (1859-1924), the founding father of artificial parthogenesis, faced negative public opinion when he published his research in 1899. His research, the public’s response to his findings, and his ethical foundations serve as an historical argument both for the communication of science and compromise in biological research.
ISSN:1473-4257
Contains:Enthalten in: Journal of medical ethics
Persistent identifiers:DOI: 10.1136/jme.2004.010199